Viking Therapeutics is trading 32.51% up at $39.90 after gaining 3.86% on September 21, 2026, with the move appearing mainly tied to continued biotech and broader risk-on momentum.
- No new company-specific announcement was identified for September 22, 2026.
- Declining oil prices and Treasury yields are also supporting sentiment.
- Oppenheimer reiterated an Outperform rating and $100 price target on September 21, potentially reinforcing interest in upcoming VK2735 maintenance data.